Acceleron Pharma Inc.
- Jurisdiction
United States - LEI
529900TQRID2UY164805 - ISIN
US00434H1086 (XLRN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€97.15M - Gross margin
100.0% - EBIT
-€220.12M - EBIT margin
-226.6% - Net income
-€219.57M - Net margin
-226.0%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: August 8, 2021